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Background: Heritable Thoracic Aortic Disorders (H-TAD) may present clinically as part of a syndromic entity or as
an isolated (nonsyndromic) manifestation. About one dozen genes are now available for clinical molecular testing.
Targeted single gene testing is hampered by significant clinical overlap between syndromic H-TAD entities and the
absence of discriminating features in isolated cases. Therefore panel testing of multiple genes has now emerged as
the preferred approach. So far, no data on mutation detection rate with this technique have been reported.
Methods: We performed Next Generation Sequencing (NGS) based screening of the seven currently most prevalent
H-TAD-associated genes (FBN1, TGFBR1/2, TGFB2, SMAD3, ACTA2 and COL3A1) on 264 samples from unrelated probands
referred for H-TAD and related entities. Patients fulfilling the criteria for Marfan syndrome (MFS) were only included if
targeted FBN1 sequencing and MLPA analysis were negative.
Results: A mutation was identified in 34 patients (13%): 12 FBN1, one TGFBR1, two TGFBR2, three TGFB2, nine SMAD3,
four ACTA2 and three COL3A1 mutations. We found mutations in FBN1 (N = 3), TGFBR2 (N = 1) and COL3A1 (N = 2) in
patients without characteristic clinical features of syndromal H-TAD. Six TAD patients harboring a mutation in SMAD3
and one TAD patient with a TGFB2 mutation fulfilled the diagnostic criteria for MFS.
Conclusion: NGS based H-TAD panel testing efficiently reveals a mutation in 13% of patients. Our observations
emphasize the clinical overlap between patients harboring mutations in syndromic and nonsyndromic H-TAD
related genes as well as within syndromic H-TAD entities, justifying a widespread application of this technique.
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mutation detection rateBackground
Thoracic Aortic Disorders (TAD), comprising aneurysms
and dissections of the thoracic aorta (ascending, arch or
descending part), are a prominent cause of morbidity
and mortality entailing 0.5-1% of all-cause mortality in
the Western World [1,2]. The etiology of TAD is complex
and heterogeneous. Both genetic and acquired forms can
be distinguished. The genetically determined forms can be
categorized into syndromic and nonsyndromic heritable* Correspondence: laurence.campens@ugent.be
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unless otherwise stated.TAD (H-TAD), depending on the presence or absence of
manifestations in other organ systems.
The prototype for syndromic H-TAD is Marfan syn-
drome (MFS), a multisystem disorder primarily affecting
the ocular, skeletal and cardiovascular system. The main
cause of morbidity and mortality in MFS is related to
progressive dilatation and ensuing dissection of the aortic
root. The diagnosis of MFS is based on the identification
of clinical manifestations, as defined in the revised Ghent
nosology, and may be supplemented with the identifica-
tion of an underlying mutation in the FBN1 gene, encod-
ing the fibrillin-1 protein [3].
Over the last decade, many related syndromic H-TAD
entities have been identified including Loeys-Dietzral. This is an Open Access article distributed under the terms of the Creative
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coding the TGFβ receptors 1 and 2 (TGFBR1/2). LDS is
characterized in its most typical form by widespread
arterial disease, arterial tortuosity, marfanoid features,
hypertelorism and cleft palate/bifid uvula [4-6]. The
clinical features of LDS show overlap, not only with MFS,
but also with those of TGFβ-signaling related H-TAD
entities [7], namely Aneurysm-Osteoarthritis syndrome
(AOS), caused by SMAD3 mutations, and H-TAD
caused by mutations in the TGFβ2 ligand. TGFB2 mu-
tations were identified in several families displaying
TAD in association with marfanoid features and clinic-
ally significant mitral valve prolapse [8-10]. In AOS,
widespread arterial disease with frequent involvement
of the visceral and iliac arteries is encountered. Osteo-
arthritis is a common additional feature [11-14]. Vascular
Ehlers-Danlos (vEDS) syndrome, caused by mutations in
the COL3A1 gene, has been recognized as another import-
ant cause of widespread arterial disease. Patients with
vEDS often present with arterial dissection without prior
dilatation. Other characteristic clinical features include
digestive tract and uterine ruptures, skin involvement
(thin and translucent skin, severe easy bruising) and a
distinctive facial appearance, which are at the basis of
the Villefranche criteria [7,15-17].
Nonsyndromic H-TAD is genetically heterogeneous
and practically all genes mentioned above have been re-
ported in the context of this entity. Other associated genes
include ACTA2, MYH11, MYLK and PRKG1 [18-23], with
ACTA2 being the most prevalent one [24]. By defin-
ition, patients/families with nonsyndromic H-TAD will
not present additional clinical manifestations although
in some cases, other cardiovascular lesions, such as bi-
cuspid aortic valve (BAV) and persistent ductus arteriosus
(PDA) occur more frequently in MYH11 and ACTA2 re-
lated H-TAD. Mutations in the ACTA2 gene trigger in-
appropriate proliferation of vascular smooth muscle cells
leading to occlusive diseases such as coronary artery
disease, stroke, Moyamoya disease and livedo reticularis.
Additionally, iris floccule has been reported in ACTA2
mutation carriers [18,19,25]. A very specific syndromic en-
tity caused by the Arg179His ACTA2 mutation is charac-
terized by an early onset severe phenotype due to global
smooth muscle cell dysfunction with PDA, congenital my-
driasis, variable presentation of pulmonary hypertension,
bladder and gastrointestinal problems and distinctive cere-
brovascular features [26,27].
Often, the absence of gene-specific clinical manifestations
and the large number of plausible genes hamper targeted
gene testing in H-TAD, resulting in a time consuming and
costly process. The need for high-throughput techniques
enabling simultaneous testing of several genes was met by
the progress made in the field of Next Generation Sequen-
cing (NGS). Previously, our center reported a mutationanalysis strategy using parallel sequencing of FBN1 and
TGFBR1 and −2 for the molecular diagnosis of MFS and
LDS, respectively [28]. This method turned out to be time-
and cost-effective compared to the conventional Sanger
method [28]. In a next step, we implemented a novel mo-
lecular analysis strategy allowing simultaneous sequencing
of seven H-TAD-associated genes‚ namely FBN1, TGFBR1/
2,TGFB2, SMAD3, ACTA2 and COL3A1.
Here we provide data on the mutation detection rate
with gene panel screening in a large cohort of patients
referred for genetic testing for H-TAD and related phe-
notypes. Based on these findings, we propose a practical
guideline for clinical evaluation and genetic testing.
Methods
Between November 2012 and April 2014, 264 consecu-
tive samples of unrelated probands were sent to our center
for H-TAD gene panel testing. Each patient was examined
by his or her referring physician. For patients seen at the
Center of Medical Genetics Ghent (CMGG) (N = 135),
detailed phenotypic information was recorded in the
patients’ electronic medical record. For patients referred
from outside the CMGG, phenotypic information was
provided by the referring physician (both geneticists
and non-geneticists) via a check-list specific for H-TAD
(Additional file 1), which included age, gender, suspected
diagnosis, specifications regarding aortic/vascular disease
and the option to indicate any observed phenotypic fea-
ture, including those listed in the revised Ghent nosology,
and a pedigree [3]. Throughout the article patients pre-
senting marfanoid features (systemic score ≥3a and/or EL),
LDS features (hypertelorism, bifid uvula and/or arterial
tortuosity) and/or vascular EDS features (facial and/or
skin features) are considered as syndromic patients. The
term ‘distal aneurysms and dissections’ (DAD) refers to
dilatation and/or dissection of arteries outside the thoracic
aorta. A positive family history is defined as the presence
of TAD in at least one 1st degree relative.
For patients fulfilling the revised Ghent criteria, targeted
gene analysis is initiated, followed by MLPA if targeted
gene analysis turns out negative. Panel testing is per-
formed whenever overlapping and/or insufficient clinical
features are present or when initial targeted gene testing
and MLPA turns out negative in patients fulfilling the re-
vised Ghent criteria.
NGS
Seven genes associated with most commonly occurring
and phenotypically overlapping syndromic and nonsyn-
dromic H-TAD entities‚ were included in the panel; namely
FBN1, TGFBR1, TGFBR2, TGFB2, SMAD3, ACTA2 and
COL3A1. Genes associated with a phenotype in which
TAD is not the main characteristic, were not included (e.g.
cutis laxa genes). New genes identified during the study
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robust patient cohort in whom the same set of genes
was tested. All coding regions and flanking sequences
of each of the seven genes are PCR amplified in a fully
automated fashion under identical reaction conditions.
A high throughput PCR based approach was used for
target enrichment. Primers were designed with PrimerXL
(www.primerXL.org). In total 157 assays are used to cover
the complete coding and splice site regions of the seven
genes included in the panel.
PCRs are performed in 10 μl total volume. Uniform
amplification conditions were applied. The PCR mixture
consists out of 5 μl of KAPA2G Robust HotStart Ready-
Mix (2×, KAPABiosystems), 50 ng of DNA template and
2.5 μl of 1 μM forward en reverse primer (IDT). The
temperature cycling protocol consists of initial denatur-
ation step at 95°C for 3 min, followed by 35 cycles of de-
naturation at 95°C for 15 sec, annealing at 60°C for
10 sec, and an extension at 72°C for 15 sec. Final exten-
sion was accomplished at 72°C for 1 min. In a next step,
all products are pooled and Next Generation Sequencing
(NGS) using the Nextera protocol (Illumina) was per-
formed on a MiSeq sequencer (Illumina). The sequence
data was processed by a bioinformatic pipeline including
the CLC bio Workbench 6.0.
Twelve samples were processed at the time. Minimal
sequencing depth was set at 20× coverage. The overall
mean coverage depth in our NGS approach was between
300x and 800x for all amplicons in the set of 7 genes.
Three percent of the total number of exons in all patients
scored below the targeted depth of 20×. These few
amplicons (fragments differ from analysis to analysis),
with incomplete coverage, were immediately analyzed
with Sanger after the Miseq run [28]. This method en-
ables a turn-around-time of approximately 8 weeks.
All mutations and unclassified variants found by NGS
were confirmed on an independent DNA sample by Sanger
sequencing.
NGS was completed for all genes in all cases, also
when a mutation was identified.
Pathogenicity assignment
The following information was obtained for each non-
synonymous variant to determine pathogenicity: (1) the
outcome of missense predictions tools (SIFT, PolyPhen2,
Grantham Distance, Align GVGD, Mutation Taster), that
are based on sequence homology, the physicochemical
similarity between the alternate amino acids, effect of an
amino acid substitution on the structure and function of
a protein and conservation level of the amino acid resi-
due amongst species, in case of mutations predicted to
result in an amino acid substitution; (2) frequency of the
variant in control alleles; (3) literature research including
relevant phenotypic information, segregation studies andfunctional data. Variant segregation analysis was performed
if DNA samples of affected and non-affected family mem-
bers were available. For a variant possibly affecting a splice
site the splicing effect at cDNA level was verified if cDNA
of the patient was available.
Variants were considered as disease causing when there
was convincing evidence from the above mentioned
criteria about their pathogenicity. In most cases, a com-
bination of different independent variant characteristics,
supported the final decision.
When data remained inconclusive, the variant was clas-
sified as a variant of unknown significance (VUS). Data
regarding the predicted pathogenicity of non-cysteine
missense mutations in FBN1, of missense mutations in
the other panel genes – not previously reported/provided
by an rs number – and of VUS in FBN1 are provided in
Additional file 2.Statistics
The number of patients presenting a specific feature is
given together with the number of patients in whom in-
formation regarding the particular feature was present
(percentage in parentheses). χ2 and Fisher’s Exact tests
were used to compare categorical variables. Data were
analyzed with the unpaired sample t-test for normal-
distributed continuous variables; non-normal distributed
variables were compared using the Mann–Whitney-U test.
Logistic regression analysis was applied to identify predic-
tors for a positive genetic test result. A p-value of < 0.05
was used to define statistical significance (two-sided).
The study was approved by the ethical committee of
the Ghent University Hospital.Results
Two hundred and sixty-four patients were included in
the study (median age 42 years, IQR 28 – 52y). TAD was
present in 233 patients (88%). In these TAD cases a posi-
tive family history for TAD was present in 27% (N = 62)
and syndromic features were reported in 33% (N = 78).
Ten percent of cases (N = 24) had both a positive family
history and syndromic features. The group of non-TAD
patients (N = 31) had either (1) DAD (N= 23) – in 2 of
them associated with a positive family history for TAD
and in 3 others with syndromic features or (2) syndromic
features without DAD (N= 8) – in four of them associated
with a positive family history for TAD.
A causal mutation could be identified in 34 patients
(13%): 12 FBN1 (35.3%), one TGFBR1 (2.9%), two TGFBR2
(5.9%), three TGFB2 (8.8%), nine SMAD3 (26.5%), three
COL3A1 (8.8%) and four ACTA2 (11.8%) mutations. Add-
itionally, we found six VUS in FBN1. An overview of the
different genotypes and clinical characteristics of mutation
positive patients is provided in Tables 1 and 2, respectively.
Table 1 Overview of mutations found in the different genes of the H-TAD panel and their associated phenotype
ID Age MUTATIONS Phenotype Age VUS Phenotype
Nucleotide change Protein change Nucleotide change Protein change
FBN1 1 27 c.1879C > T [29] p.(Arg627Cys) S H-TAD 11 c.860A > G* p.Glu287Gly NS H-TAD
2 1 c.3601 T > C* p.(Cys1201Arg) S H-TAD 16 c.2819G > T* p.Gly940Val S H-TAD
3 3 c.4459 + 1G > C* / S H-TAD 56 c.3748G > T* p.Asp1250Tyr NS H-TAD
4 54 c.5377 T > A* p.(Cys1793Ser) S H-TAD 32 c.4347G > T* p.Glu1449Asp NS H-TAD
5 1 c.5558G > C* p.(Cys1853Ser) S H-TAD 47 c.7379A > G [30] p.Lys2460Arg NS H-TAD
6 23 c.6496 + 1 G > A* / S H-TAD 39 c.7412C > G* p.Pro2471Arg NS H-TAD
7 34 c.6952 T > C [29] p.(Cys2318Arg) NS H-TAD
8 52 c.7486 T > A* p.(Cys2496Ser) NS H-TAD
9 54 c.7486 T > A* p.(Cys2496Ser) NS H-TAD
10 40 c.7852G > A [31-33] p.(Gly2618Arg) TAD - SS a/o EL?
11 16 c.8536G > T* p.(Glu2846X) S H-TAD
12 8 c.8544dupA* p.(Tyr2849IlefsX2) S H-TAD
TGFBR1 13 23 c.683_685delAAG [34] p.(Glu228del) S H-TAD
TGFBR2 14 39 c.1084C > A* p.(His362Asn) S H-TAD
15 81 c.1379G > A [35] p.(Arg460His) NS DAD
TGFB2 16 27 c.577C > T* p.(Arg193Trp) S H-TAD
17 48 c.980G > A [9] p.(Arg327Gln) S H-TAD
18 3 c.988C > T [10] p.(Arg330Cys) S H-TAD
SMAD3 19 20 c.401-6G > A [36] / S H-TAD
20 53 c.546delT* p.(Gly183AlafsX3) S H-TAD
21 24 c.584_585insTC* p.(Gln195HisfsX3) S H-TAD
22 24 c.715G > A [37] p.(Glu239Lys) S H-TAD
23 53 c.715G > A [37] p.(Glu239Lys) S H-TAD
24 23 c.715G > A [37] p.(Glu239Lys) S H-TAD
25 14 c.859C > T [13] p.(Arg287Trp) S H-TAD
26 32 c.887 T > C* p.(Leu296Pro) S H-TAD
27 20 c.1155-2A > G* / S H-TAD
ACTA2 28 61 c.115C > T [19,38] p.(Arg39Cys) NS H-TAD
29 17 c.455C > T [18] p.(Arg149Cys) NS H-TAD
30 59 c.772C > T [25] p.(Arg258Cys) NS H-TAD
31 32 c.910G > A [38] p.(Gly304Ser) NS H-TAD
COL3A1 32 40 c.3410G > A [39] p.(Gly1137Asp) NS DAD
33 43 c.719G > T* p.(Gly240Val) NS H-TAD
34 35 c.811 C > T* p.(Arg271X) S-H-TAD
(N)S H-TAD: (Non) Syndromic HTAD; NS DAD: Nonsyndromic distal aneurysms and dissections. SS a/o EL?: no info on the systemic score of Marfan syndrome and/or
ophthalmological info available. *novel mutation, i.e. not previously reported in literature and not previously found in our lab. Age is expressed in years.
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mutation carriers (85%), in whom a positive family his-
tory for TAD was present in 45% (N = 13), syndromic
features were reported in 69% (N = 20), 28% of patients
(N = 8) had both a positive family history and syndromic
features and 17% of patients (N = 5) had no known fam-
ily history for TAD and no syndromic features. The five
remaining patients demonstrated DAD (N = 2 – onewith positive family history for TAD) or syndromic fea-
tures (N = 3 – one with positive family history for TAD).
In Table 3, we compared the demographic and clinical
characteristics in patients with and without a mutation
in the seven H-TAD genes (in Additional file 3 children
are presented separately from adult cases). There was a
male preponderance in the study cohort, presumably
due to an up to two times higher prevalence of TAD in
Table 2 Overview clinical features per genotype
MFS features LDS
features
vEDS TAD MVP DAD FH TAD
SS EL
SS1-2 SS3-6 SS ≥ 7
FBN1 (N = 12) / 5/11 3/11 - 1 1 10 3 - 4/8
TGFBR1 (N = 1) + / / - + - + - - -
TGFBR2 (N = 2) 1 / / - 1 - 1 - 1 1
TGFB2 (N = 3) / 2 1 - - - 3 1 1 2
SMAD3 (N = 9) 1 2 6 - 1 - 8 3 - 6/8
ACTA2 (N = 4) / / / - - 4 - 1 2/3
COL3A1 (N = 3) - - 1 2 - 2 -
DAD: distal aneurysms a/o dissections; EL: ectopia lentis; FH TAD: positive family history for thoracic aneurysms and dissections; MVP: mitral valve prolapse; SS:
systemic score; TAD: thoracic aneurysms and dissections. MFS (Marfan syndrome) features i.e. systemic features and/or ectopia lentis, LDS (Loeys-Dietz syndrome)
features i.e. hypertelorism, bifid uvula and/or arterial tortuosity, vEDS (Ehlers-Danlos syndrome) features i.e. facial and/or skin features.
The number of patients of whom clinical data was provided is given whenever data regarding a specific features was not available for all patients.
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diagnosis of cardiovascular disease in woman in general
[1,40-42]. A positive family history, age and presence of
syndromic features (as specified in the method section),
were identified as the strongest predictors for a positive
genetic test result using logistic regression analysis (p =
0.001 to 0.01). The regression model, in which age, fam-
ily history and presence of syndromic features were in-
cluded, indicated an approximately three times higher
chance of finding a mutation when the family historyTable 3 Main clinical characteristics of mutation negative
and mutation positive patients
Mutation negativea
(N = 224)
Mutation positive
(N = 34)
p-value
Age (years) 41.8 (17.0) 31.9 (19.5) 0.004
Female gender 63/224 17/34 0.01
TAD 199/224 29/34 0.55
DAD 52/224 5/34 0.27
Family history
for TAD
52/179 15/28 0.01
Systemic score
1-2 47/164 3/33 0.018
3-6 45/164 9/33 0.98
≥7 13/164 10/33 <0.001
Mitral valve
prolapse
23/216 7/34 0.097
Bifid uvula 2/139 2/15 0.048
Hypertelorism 5/224 3/34 0.039
Arterial tortuosity 12/77 0/7 0.26
Skin a/o facial
features vEDS
15/142 2/19 0.99
aPatients in whom a VUS was identified are not included in Table 3.
DAD: distal aneurysms a/o dissections; TAD: thoracic aortic disease; vEDS:
vascular Ehlers-Danlos syndrome. Age is presented as mean with standard
deviation in parentheses, the number of patients positive for the respective feature
and the number of patients of whom clinical data was provided, is given.for TAD was positive or when syndromic features were
present (p = 0.033 and 0.035 – Additional file 4). Age
was no significant independent predictor in this model
(p = 0.092 – Additional file 4).
Of the 12 patients harboring an FBN1 mutation, eight
had a clinical suspicion for MFS prior to the molecular
test, but did not fulfil the revised Ghent criteria (N = 6)
or demonstrated overlapping features with other syndromic
entities (N = 2) (Table 2). The four remaining FBN1 pa-
tients all presented TAD, three of them demonstrated no
syndromic features (systemic score of 0 – no EL); in one
patient no information on the MFS systemic score and/or
ophthalmological findings was provided.
Nineteen patients, in whom no mutation in FBN1 could
be identified, fulfilled the revised Ghent criteria. Subse-
quent panel testing revealed mutations in SMAD3 (N = 6)
and in TGFB2 (N = 1). The remaining patients with a
SMAD3 (N = 3) and with a TGFB2 (N = 2) mutation
demonstrated some marfanoid features (Table 2).
One ACTA2 mutation carrier demonstrated coronary
artery disease, but other features associated with ACTA2
mutations [24] were either not present or not reported.
None of the patients with a TGFBR1 or 2 mutation
demonstrated the classic LDS trias (hypertelorism, cleft
palate/bifid uvula and aortic/arterial aneurysms/tortuosity),
but two of them did present some particular LDS features
such as hypertelorism or bifid uvula. Surprisingly, two out
of the three patients with a COL3A1 mutation did not
present skin or facial features reminiscent of vascular
Ehlers-Danlos Syndrome (vEDS). One of them, previ-
ously diagnosed with a type A aortic dissection at the
age of 31, presented with a spontaneous rupture of an
intercostal artery. The second vEDS patient, who did
not fulfil the Villefranche criteria, presented at 40 years
of age with simultaneous dissections of several visceral
side branches of the aorta (superior mesenterial artery,
truncus coeliacus and right common iliacal artery). His
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as both his mother and sister had died suddenly of an
arterial dissection outside the aorta. The third COL3A1
patient, carrying a null mutation (Table 1), did present
facial vEDS characteristics. He presented a type B aortic
dissection at 35 years of age. His brother experienced a
coronary artery dissection at 37 years of age.
In the patients in whom a VUS in FBN1 was identified,
TAD was reported in all but one (Table 1). This particu-
lar patient, 16 years of age, was the only patient with a
VUS who demonstrated skeletal features reminiscent of
MFS. Pathogenicity data of all VUS are provided in
Additional file 2.
Eight patients referred for panel testing had isolated
intracerebral aneurysm/dissection or dissection of the
neck arteries without syndromic features and a negative
family history for TAD. Panel testing was negative in all
of them.
In total, 34 patients in the study cohort had a bicuspid
aortic valve (BAV), all but one with associated ascending
aortic dilatation. In six patients a positive family history
and in six syndromic features were reported. Panel test-
ing was negative in all BAV patients.
Discussion and conclusions
The identification of a causal mutation underlying
H-TAD is important with regard to management and the
evaluation of relatives at risk. We report on the results of
NGS-based panel testing of the 7 most frequently re-
ported H-TAD genes in a cohort of 264 unrelated
individuals.
The primary purpose of our study was to determine
the mutation detection rate in a representative sample of
patients referred to a large genetic center for clinical gen-
etic testing for H-TAD and related disorders. The overall
mutation detection rate in the total cohort and in the sub-
group of H-TAD patients was 13 and 12%, respectively.
The majority of mutation positive patients harbored
mutations in FBN1 (35.3%) and SMAD3 (26.5%). To the
best of our knowledge this is the first time that such a
high mutation detection rate for SMAD3 in an H-TAD
cohort is reported. The patients in whom an FBN1 muta-
tion was identified by panel testing (N = 12), did not fulfil
the revised Ghent criteria (prior to molecular testing) or
demonstrated overlapping features with other H-TAD re-
lated entities. Panel sequencing allowed us to establish the
diagnosis of MFS – following the revised Ghent criteria –
in 10 of them. Targeted FBN1 gene analysis is in general
initiated in those patients who clearly fulfill the diagnostic
criteria for MFS (prior to molecular testing) and who do
not present specific clinical features triggering another
syndromic diagnosis, because of a high pretest probability
of finding an FBN1 mutation in this particular population
[28]. If targeted screening and MLPA turn out negative;NGS is initiated. Since the introduction of the H-TAD
panel in our lab and thus start of inclusion for the current
study 57 mutations have been identified with targeted
FBN1 analysis and three with MLPA (not included in the
current study). This implicates that mutations in this gene
remain the most frequent cause of syndromic H-TAD and
further supports targeted gene analysis in clear cases of
MFS. Remarkably, patients fulfilling the revised Ghent
criteria may also harbor mutations in other H-TAD
genes, as evidenced by a notable number of SMAD3
mutations (N = 6) and one TGFB2 mutation on a total
of 19 FBN1 negative patients. These findings emphasize
the clinical overlap between syndromic H-TAD entities
and warrant NGS panel testing in patients negative for
initial targeted gene analysis.
Patients presenting with nonsyndromic H-TAD (N =
155) may harbor mutations in any of the known H-
TAD genes. In addition to previously reported FBN1,
TGFBR1/2, TGFB2, SMAD3 and ACTA2 mutations
[9,12,18,19,24,35,43], we report on a COL3A1 mutation
in a nonsyndromic H-TAD patient. The mutation detec-
tion rate in the FBN1 gene in the nonsyndromic H-TAD
patient group (1.9%) is in line with previously published
data [44]. The mutation detection rate in ACTA2 (2.6%)
contrasts with what has been reported in the first studies
identifying ACTA2 mutations in up to 16% of nonsyn-
dromic H-TAD families [18-20]. This discrepancy may be
due to differences in study design and patient ascertain-
ment. Our results are in line with more recent studies per-
formed in similar patient populations [44].
In the group of non-TAD patients presenting DAD at
the time of diagnosis (N = 21) we found one COL3A1
and one TGFBR2 mutation. The finding of COL3A1
mutations in patients without any facial or skin features
evocative for vEDS is quite remarkable and warrants a
high index of suspicion for the disease among treating
physicians.
In patients presenting syndromic features in the ab-
sence of TAD and DAD at the time of diagnosis (N = 8),
two FBN1 and one SMAD3 mutation were found. These
were all young patients (age range 16–23 years), in
whom aortic disease had not yet developed.
Most of the FBN1 mutations found in our cohort were
substitutions of a highly conserved cysteine residue in-
volving a cb-EGF-like domain, which is the most com-
mon pathogenic FBN1 mutation type [29]. Two intronic
mutations at the consensus splice site residues +1 were
identified and four patients demonstrated a mutation
leading to a premature termination codon. In three pa-
tients a substitution of a non-cysteine amino acid was
found. Most COL3A1 mutations are glycine substitu-
tions leading to disruption of the triple helix structure of
type III collagen [7], and were identified in two of our
patients. In a minority of vEDS patients COL3A1 null
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Those patients generally present with a milder clinical
phenotype with delayed onset of arterial complications,
less visceral complications and less commonly characteris-
tic skin and/or facial features [46-48]. The case we describe
here, demonstrates early onset arterial disease with some
facial features reminiscent of vEDS, but without other
major and minor diagnostic criteria for vEDS [17].
In most cases, interpretation of the functional conse-
quence of typical mutations in FBN1 (cysteine missense
mutations) and in COL3A1 (glycine missense mutations)
is clear-cut. However, a significant proportion of vari-
ants, named VUS, consists of ‘atypical’ missense changes
or potential splice-site changes of uncertain biologic or
clinical relevance. The challenging issue remains how to
use these data in clinical practice.
In the current era of high-throughput molecular genetic
techniques, knowledge of the indications and limitations
for these tests in daily clinical practice is increasingly im-
portant. Pending guidelines, supported by an international
expert panel, we suggest the following recommendations
for clinical evaluation and for guiding clinicians in their
decision to refer patients, presenting with TAD and/or
DAD, for panel testing:
– Genetic counseling is recommended for all patients
with TAD when their disease cannot be explained
solely by non-genetic causes
– It is recommended to clinically investigate first
degree relatives (siblings – parents – offspring) of a
subject with TAD to identify familial forms [49,50]
– Panel testing is recommended in patients presenting
TAD/DAD and with a positive family history of
TAD, to investigate the molecular cause underlying
the H-TAD
– In patients fulfilling the revised Ghent criteria, targeted
FBN1 analysis can be considered prior to panel testing
– In patients without TAD presenting syndromic
features suggestive of H-TAD b and a positive family
history of TAD, panel testing is recommended c, to
investigate the molecular cause underlying the H-TAD
– In isolated (non-familial), non-syndromic TAD, panel
testing can be considered if the disease is not due to a
high cardiovascular risk profile d and if genetic testing
of their relatives is relevant
– In isolated (non-familial), non-syndromic DAD
(with the exclusion of single aneurysms/dissections
of head/neck arteries and abdominal aorta e), panel
testing can be considered if the disease is not due
to a high cardiovascular risk profile d and if genetic
testing of their relatives is relevant
– It is recommended that genetic testing is performed
in certified diagnostic laboratories with expertise in
interpretation of H-TAD-related mutations– In patients with non-syndromic TAD associated
with BAV in the absence of a positive family history,
panel testing is not routinely recommended
– In young patients (<30 years), presenting syndromic
features b (not fulfilling the revised Ghent criteria),
but no TAD/DAD and no family history of TAD, the
threshold for clinical follow-up should in general be
kept low.
Conclusion
It is clear that the development and implementation of
these new technologies in the diagnostics of H-TAD
leads to a more time- and cost-efficient strategy to iden-
tify disease causing mutations. The turnaround time for
the NGS panel is approximately 8 weeks, which is clearly
shorter than the conventional method with Sanger
(~12 weeks/gene), and the reagent cost per amplicon is
about 4 times lower with NGS. In selected cases with a
high pre-test probability of an FBN1 mutation, for
instance patients fulfilling the revised Ghent criteria
including the presence of ectopia lentis, targeted gene
testing is still justified. At least, we recommend panel
testing in those cases where the phenotype is not
conclusive or when initial targeted gene analysis did not
reveal a mutation.
Limitations
The NGS technology fails to detect larger deletions or in-
sertions. Therefore, mutation-negative samples of patients
with a high clinical suspicion should still be evaluated by a
complementary technique, such as MLPA [28]. MLPA of
FBN1 was performed prior to inclusion in the study in
patients fulfilling the revised Ghent criteria who were
negative for targeted FBN1 analysis. MLPA of the other
panel genes was not performed. Therefore the number of
mutation positive patients could be slightly underestimated.
It is not excluded that mutation negative patients carry
a pathogenic mutation in a gene‚ not included in the
current panel. The mutation detection rate presented
here could therefore be somewhat underestimated. Se-
quencing of a second gene panel, comprising the more
rare H-TAD genes and genes that are associated with a
phenotype, in which TAD is not a primary feature, is on-
going. Our diagnostic panel has been expanded now to
include MYH11, TGFB3, PRKG1 and MLCK.
Consent
Informed consent was obtained from all patients and the
Declaration of Helsinki protocols were followed.
Endnotes
aA systemic score of 3 or more was considered as a
marfanoid phenotype.
Campens et al. Orphanet Journal of Rare Diseases  (2015) 10:9 Page 8 of 9bSyndromic features MFS (skeletal features – EL) –
LDS features (hypertelorism, bifid uvula a/o arterial tor-
tuosity) – vEDS features (skin a/o facial vEDS features).
cYoung patients (<30 years) may not yet present TAD,
therefore the threshold for genetic testing should re-
main low whenever a suspicious family history or con-
vincing and specific syndromic features - such as EL - are
present.
dHigh cardiovascular risk: untreated arterial hyperten-
sion + ≥1 CV risk factor OR ≥3 CV risk factors (CV risk
factors: BMI > 30 kg/m2, diabetes, arterial hypertension,
hyperlipidemia, smoking and positive family history for
coronary artery disease).
eIsolated aneurysm/dissection of the abdominal aorta
or an intracranial or neck artery is less suspicious for
H-TAD than aneurysm/atraumatic dissection of middle
and small sized thoracic and/or abdominal arteries.
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